Therapeutic Efficacy of Standardized Ethanolic Extract of Eclipta prostrata in Streptozotocin-Induced Diabetic Rats
International Journal of Drug Delivery Technology · 28.04.2026 · 16 (22s)
DOI: 10.25258/ijddt.16.22s.66 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 28.04.2026. Verfasst von Amar Jeet Ram und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
The clinical management of diabetes mellitus necessitates multi-targeted therapeutic strategies capable of not only maintaining glycemic control but also arresting severe secondary complications, including atherogenic dyslipidemia and progressive organ damage.
Objective
To systematically evaluate the antihyperglycemic, hypolipidemic, and dual hepato-renal protective efficacy of a polyphenol-standardized ethanolic extract of Eclipta prostrata in a streptozotocin (STZ)-induced diabetic rat model.
Methods
Following acute oral toxicity profiling (OECD Guideline 423), diabetes was induced in male Wistar rats via a single STZ injection (55 mg/kg, i.p.). The diabetic cohorts received oral administration of the extract (200 and 400 mg/kg) or the standard drug glibenclamide (5 mg/kg) daily for 28 days. Therapeutic efficacy was assessed through the quantification of fasting blood glucose (FBG), serum insulin, glycosylated haemoglobin (HbA1c), comprehensive lipid profiles, and hepato-renal biochemical markers (ALT, AST, urea, creatinine). These findings were corroborated by rigorous histopathological examination of the pancreas, liver, and kidneys.
Results
The extract was classified as safe up to a limit dose of 2000 mg/kg. The 28-day intervention elicited a significant, dose-dependent reduction in FBG and HbA1c, alongside a robust restoration of endogenous serum insulin levels. Furthermore, the extract effectively reversed STZ-induced dyslipidemia (significantly lowering TC, TG, LDL, and elevating HDL) and normalized hepato-renal injury markers. Microscopic evaluation visually confirmed structural β-cell regeneration, attenuation of hepatic microvesicular steatosis, and preservation of renal glomerular architecture.
Conclusion
The standardized E. prostrata extract functions as a potent, multi-targeted phytotherapeutic agent. By simultaneously ameliorating systemic hyperglycemia, correcting dyslipidemia, and mitigating oxidative hepatorenal tissue damage, it presents a viable and comprehensive pharmacological strategy for managing diabetic metabolic syndrome
Zitieren
APA
Ram, A. J., & Jain, G. (2026). Therapeutic Efficacy of Standardized Ethanolic Extract of Eclipta prostrata in Streptozotocin-Induced Diabetic Rats. International Journal of Drug Delivery Technology, 16(22s). https://doi.org/10.25258/ijddt.16.22s.66
Vancouver
Ram AJ, Jain G. Therapeutic Efficacy of Standardized Ethanolic Extract of Eclipta prostrata in Streptozotocin-Induced Diabetic Rats. International Journal of Drug Delivery Technology. 2026;16(22s). doi:10.25258/ijddt.16.22s.66
BibTeX
@article{Ram2026,
author = {Ram, Amar Jeet and Jain, Gaurav},
title = {Therapeutic Efficacy of Standardized Ethanolic Extract of Eclipta prostrata in Streptozotocin-Induced Diabetic Rats},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {22s},
doi = {10.25258/ijddt.16.22s.66}
}
EUVIMED